COVID-19: Victorian patients

15 July 2020: Genea has been advised by the Department of Health and Human Services that from today Wednesday 15 July 2020, all Victorian patients living, or working within a Stage 3 restriction zone or other known hotspot, will need to be tested for COVID-19 before being admitted to hospital, including for fertility treatment (IUI, OPU, ET, FET and sperm aspiration). Patients are required to self-isolate following testing until their procedure.

General Manager of Operations, Kathleen Waite said, “Genea nurses are making contact with all affected patients and helping to coordinate testing as soon as possible to minimise disruption to treatment.” Ms Waite encouraged all patients to come forward if they had any questions. She added, “we will continue to do our best to keep our patients and staff safe and healthy.”

Download a PDF of the press release
Meline Walton
Media & Communications Manager
M: +61 452 433 369

About Genea
Genea is one of Australia’s leading providers for infertility, IVF and other assisted conception treatment with 33 years of experience in the field. The company has long been a fertility pioneer, with research and technologies developed in-house virtually doubling IVF success rates in the mid-nineties and continuing to improve outcomes today. In July 2018, Genea was the highest ranked healthcare provider named on Australian Financial Review’s Top 100 Most Innovative Companies List, ranked number 18.

Genea’s sister company, Genea Biomedx creates and manufactures practical, accessible and precise fertility technologies that help standardise and automate fertility treatment. Its unique relationship with Genea Fertility means that Genea Biomedx is a manufacturer that truly understands the customers’ perspective. As a result, Genea Biomedx has developed the world’s first automated vitrification instrument and has created a world leading benchtop incubator with timelapse functionality.

About Gavi, Geri, Gems and Gidget
  • Gavi – the world’s first automated vitrification instrument; Vitrification is a process used in IVF to preserve human egg cells (ooc ytes) or embryos by cooling them to deep sub-zero degrees. Approaching the process in an innovative way, Gavi uses an automated, standardized protocol aiming to provide consistent results in blastocyst vitrification.
  • Geri - a benchtop incubator with individually controlled incubation chambers per patient to minimize disruptive events to the early-stage embryo. It also incorporates a camera for continuous monitoring of embryos as they develop.
  • Gems - the latest generation of Genea’s culture media for embryo cultivation.
  • Gidget - an innovative witnessing and tracking system that provides electronic witnessing, lab workflow management and support for traceability and audit reporting.